PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (Nasdaq:ARWR) announced today that Edward Jacobs, Chief Executive Officer and President of Insert Therapeutics, a majority-owned subsidiary of Arrowhead, will present at the May 18th Annual Institutional Investor Conference at the Princeton Club in New York City on May 22, 2007. Mr. Jacobs’ presentation, entitled “Insert Therapeutics Product Development Update,” will highlight Insert’s progress in using its proprietary polymeric transport system, CyclosertTM, to design, develop and commercialize nanoparticle-enhanced small-molecule therapeutics. Insert’s lead drug candidate, a combination of its linear, cyclodextrin-based polymer and the anti-cancer compound camptothecin, entered the clinic in 2006.
